RxDoctor Payments Data

Yazen Beddawi, MD

Critical Care Medicine · Berkeley, CANPI 1558594309

Payments from drug & device makers

$1,337in general payments, 2019–2025

Across 20 payments — averaging $66.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$735
  • AstraZeneca$253
  • Boehringer Ingelheim$136
  • Pulmonx Corporation$81
  • Sanofi$70
  • GSK$37
  • plus $25 from 1 others

What the payments were for

  • Travel & lodging$59044%
  • Food & beverage$74756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,337 in reported general payments places this provider in the 65th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$109,988
Medicare patients
231
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,183
Breo ElliptaFluticasone/Vilanterol34$15,306
Spiriva RespimatTiotropium Bromide11$7,272
SymbicortBudesonide/Formoterol Fumarate17$3,753
BreynaBudesonide/Formoterol Fumarate11$2,468
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,379
Albuterol Sulfate HfaAlbuterol Sulfate52$1,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$37$34,48965 claims
Boehringer IngelheimSpiriva Respimat$136$7,27211 claims
AstraZenecaSymbicort$253$3,75317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →